The BCR/ABL fusion gene is the most common fusion in leukemia. The BCR/ABL fusion is the hallmark of chronic myeloid leukemia and is found in about 20% of all B-lineage acute lymphoblastic leukemias (ALL). The BCR/ABL fusion leads to the constitutive activation of the ABL1 tyrosine kinase via the oligomerization of the fusion protein mediated by the coiledcoiled domain of BCR. 1, 2 Even though the ABL tyrosine kinase is one of the most frequently activated kinases in hematological malignancy, other than BCR, 3 only six additional ABL1 fusion partners have been identified: ETV6, 4 RCSD1, 5 EML1, 6 NUP214, 7 ZMIZ1 8 and SFPQ. 9 Except for NUP214, the other ABL1 fusions are rare. For RCSD1, EML1, ZMIZ1 and SFPQ, only case reports have been described. 10 Only the NUP214/ABL1 fusion is found recurrently in approximately 6% of the T-ALL cases. 7 Here, we describe the discovery and characterization of the novel ABL1 fusion to the SH2-containing inositol phosphatase-1 (SHIP1; INPP5D).
An 18-year-old woman was diagnosed with common ALL. Standard cytogenetic analysis revealed a normal karyotype of 46,XX. The routine reverse transcription-PCR screening of the patient's bone marrow mRNA for the BCR/ABL fusion transcript resulted in the amplification of a longer-than-expected PCR product (faint band Figure 1a , lane 3, white arrow). Sequence analysis of this PCR product revealed an in-frame fusion between the 5 0 portion (exon 9) of the SHIP1 gene (INPP5D) and the 3 0 portion of ABL1, starting from exon 2 ( Figure 1b) . The presence of the SHIP1/ABL1 fusion transcript was confirmed by reverse transcription-PCR, using a primer pair specific for the SHIP1/ABL1 fusion (Figure 1c) . For a detailed description of the materials and methods used in this work, please refer to the Supplementary Material.
Fluorescence in situ hybridization analysis using a commercially available BCR/ABL dual color dual fusion probe (Vysis/Abbott, Wiesbaden, Germany) revealed a normal signal pattern on metaphase chromosomes (data not shown). However, about 50% of the interphase nuclei showed four ABL1 signals, suggesting an ABL1 rearrangement (red signals in Figure 1d (I)). A dual color dual fusion SHIP1/ABL1 fluorescence in situ hybridization probe (Figure 1d (II)) revealed three fusion signals (yellow), in addition to a green and an orange signal for the normal SHIP1 and ABL1 alleles, respectively (Figure 1d (III) ). To distinguish whether these fusion signals were due to the a 5 0 -SHIP1/3 0 -ABL1 or the reciprocal 5 0 -ABL1/3 0 -SHIP1 fusion, single fusion (SF) SHIP1/ABL1 and SF ABL1/SHIP1 probes were employed. The SF SHIP1/ABL1 and the SF ABL1/SHIP1 probes indicated that the cells carried two SHIP1/ABL1 fusions (Figure 1d (IV) ) and one ABL1/SHIP1 fusion (Figure 1d (V) ).
The new fusion partner of ABL1, SHIP1 (INPP5D) encodes a protein of 1188 amino acids (aa; 145 kDa), with an N-terminal SH2 (scr-homology) domain, an inositol phosphatase domain and a C-terminal proline-rich region (Figure 1e ). The SHIP1/ABL1 fusion protein contains the first 343 aa of SHIP1, including the SH2 domain and almost the complete ABL1 protein as it is found in other ABL1 fusion proteins (for example, in BCR/ABL1) (Figure 1e) .
To determine the frequency of the SHIP1/ABL1 rearrangement in leukemia, we screened the cDNA of 63 ALL cell lines (36 pre B-ALL, 8 B-ALL and 19 T-ALL; Supplementary Table 1), using SHIP1/ABL1 fusion transcript-specific primers. None of the cell lines was positive. We expanded our search to include a series of 678 BCR/ABL-negative childhood ALL cases (age 1.4-17.4 years; mainly B-ALL), which had been examined at the cytogenetics laboratory of the University of Giessen hospital.
Fifteen of those 678 cases (2.2%) had three ABL1 fluorescence in situ hybridization signals, which could not be explained by cytogenetics (that is, þ 9 or i(9)(q10)). Only four of these samples, which corresponds to about 180 screened cases, could be successfully analyzed with our SHIP1/ABL1 dual color dual fusion probe. None of these samples exhibited a SHIP1/ABL1 rearrangement. Thus, the SHIP1/ABL1 fusion appears to be a rare event. However, more thorough studies are needed in other groups of leukemia (for example, adult B and T-ALL cases) to determine the true prevalence of this rearrangement.
Like the BCR/ABL1 fusion, expression of the SHIP1/ABL1 fusion (Supplementary Figure 1) induced IL3-independent growth in Ba/F3 cells ( Figure 2a ). Next, we tested the sensitivity of SHIP1/ABL1 to imatinib. Increasing concentrations of As most ABL1 fusion proteins are activated by dimerization, we assayed dimerization of the SHIP1/ABL1 fusion by coexpressing a FLAG-tagged and an HA-tagged version of the SHIP1/ABL1 protein in HEK293T cells. Dimerization of SHIP1/ABL1 was demonstrated by successful co-immunoprecipitation ( Figure 2d ). Next, we proceeded to map the protein domains of the N-terminal SHIP1 portion required for dimerization and divided the SHIP1 N-terminus into three domains: the SH2 domain (aa 3-99), domain D1 (aa 100-220) and domain D2 (221-340) (Figure 2e) . We tested four different deletion mutants of the N-terminal SHIP1 region for protein-protein interaction in the yeast-two-hybrid system. The yeast-two-hybrid assays demonstrated a strong interaction between domains D1 and D2 (Figure 2f, fields 9, 10, 11, 14, 20, 26) . Domains D1 and D2 are sufficient for the dimerization in the context of the SHIP1/ABL1 fusion protein (Supplementary Figure 2) , for the induction of factor independent growth of Ba/F3 cells and for the phosphorylation of downstream effector proteins (Supplementary Figure 3) .
Several lines of evidence suggest that SHIP1 has tumor suppressor gene functions. SHIP1 is a phosphatase, which negatively regulates the PI3K (phosphoinositide 3-kinase) pathway, 11 thereby negatively regulating key cellular functions such as survival, proliferation, cell activation and cell migration through its interaction with the SHC1 and GRB2 adapter protein.
11 SHIP1 knockout mice failed to thrive and developed a myeloproliferative-like disease.
12 Surprisingly, there are only very few reports about genetic alteration of SHIP1 in leukemia. [13] [14] [15] This is the first report of SHIP1 being involved in a chromosomal translocation. As we demonstrated that the N-terminus of SHIP1 is capable of dimerization, and possibly oligomerization, it can be speculated that di-or oligomerization of SHIP1 has a role in the regulation of SHIP1 function itself. It is thus conceivable that the D1-D2 interaction will also result in the formation of SHIP1/ ABL1FSHIP1 heterodimers. In this scenario, SHIP1/ABL1 might not only function as an activated tyrosine kinase oncogene, but might also influence normal SHIP1 function in a dominant negative fashion (Supplementary Figure 4) .
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